Aim: to assess the safety and efficacy of regimen of Alpha Interferon -2b (Pasture Made) plus Ribavirin in a number of Iranian patients with chronic hepatitis C. Inclusion Criteria: older than 18 years, HCV RNA in serum on polymerase-chain-reaction (PCR) assay Exclusion Criteria: decompensated cirrhosis, autoimmune disease, evidence of cancer on ultrasonography or a high serum alfa-fetoprotein concentration, co-infection with HBV or HIV, neutropenia (neutrophil count <1500 cells/mm3), thrombocytopenia (platelet count <90,000 cells/mm3), anemia (hemoglobin level <12 gr/dl for women and <13 gr/dl for men), creatinine concentration more than 1.5 times the upper limit of normal range, organ transplantation, neoplastic disease, severe cardiac or chronic pulmonary disease, poorly controlled psychiatric disorder, seizure disorder, retinopathy, active drug or alcohol abuse, pregnancy in patient or spouse or unwillingness to use contraception Sample size: 40 patients Intervention: Patients assigned to receive subcutaneous treatment with Alpha Interferon -2b (Pasture made) Every other day plus oral treatment with Ribavirin 10-15 mg/kg per day. Primary outcome: rapid virologic response (RVR)